Second Quarter 2021 Highlights
(Unless otherwise stated, all percent changes are based on year-over-year comparisons)
- Net income of
$424.6 million , or$3.62 per diluted share, including a gain on the sale of Fine Chemistry Services (FCS) business - Adjusted diluted EPS of
$0.89 , an increase of 4% - Net sales of
$773.9 million , an increase of 1%; Net sales increased 5% excludingFCS - Adjusted EBITDA of
$194.6 million , an increase of 5%; Adjusted EBITDA increased 13% excludingFCS - Full year 2021 outlook revised to reflect better than expected Lithium performance, lower interest expense and tax rates, offset by higher Bromine raw material costs and supply chain disruptions; guidance updated to reflect sale of
FCS - Completed the sale of
FCS onJune 1, 2021 , in a cash and stock transaction valued at~$570 million - La Negra III/IV commissioning stage in process, commercial production expected to begin in first half of 2022
"Albemarle delivered another strong quarter, generating
Outlook
The company continues to expect a modest improvement in operating performance compared to full year 2020, assuming continued global economic recovery. Full-year 2021 net sales guidance is improved compared to previous guidance primarily due to increased Lithium sales and improving Catalysts trends offset by reduced expectations for the Bromine business as a result of higher raw material costs and supply chain disruptions. Revised EBITDA reflects higher net sales offset by higher corporate costs, primarily related to incentive compensation expense and foreign exchange. Higher EPS and net cash from operations reflects lower interest expense and tax rates. Net cash from operations is also expected to benefit from timing of working capital changes. Capital expenditures are trending near the high-end of the range, due to tighter labor markets and COVID-related travel restrictions in Western Australia. Pro forma revised guidance has been updated to reflect the sale of Albemarle's Fine Chemistry Services (FCS) business to W. R. Grace, which closed on
Revised |
FCS Adjustment |
Pro Forma Revised |
|||
FY 2021 Guidance |
( |
FY 2021 Guidance |
|||
Net sales |
|
|
|
||
Adjusted EBITDA |
|
|
|
||
Adjusted EBITDA Margin |
24% - 25% |
24% - 25% |
|||
Adjusted Diluted EPS |
|
|
|
||
|
|
|
|
||
Capital Expenditures |
|
|
|
COVID-19 Response
Albemarle's cross-functional
Second-Quarter Results
In millions, except per share amounts |
Q2 2021 |
Q2 2020 |
$ Change |
% Change |
||||||||||
Net sales |
$ |
773.9 |
$ |
764.0 |
$ |
9.8 |
1.3 |
% |
||||||
Net income attributable to |
$ |
424.6 |
$ |
85.6 |
$ |
339.0 |
395.9 |
% |
||||||
Adjusted EBITDA(a) |
$ |
194.6 |
$ |
185.2 |
$ |
9.4 |
5.1 |
% |
||||||
Diluted earnings per share |
$ |
3.62 |
$ |
0.80 |
$ |
2.82 |
352.5 |
% |
||||||
Non-operating pension and OPEB items(a) |
(0.04) |
(0.02) |
||||||||||||
Non-recurring and other unusual items(a) |
(2.69) |
0.07 |
||||||||||||
Adjusted diluted earnings per share(b) |
$ |
0.89 |
$ |
0.86 |
$ |
0.03 |
3.5 |
% |
(a) |
See Non-GAAP Reconciliations for further details. |
(b) |
Totals may not add due to rounding. |
Net sales of
Adjusted EBITDA of
The effective income tax rate for the second quarter of 2021 was 20.0% compared to 17.5% in the same period of 2020. The difference is largely due to tax expense recorded in the second quarter of 2021 for the gain on the sale of the
Business Segment Results
Lithium
In millions |
Q2 2021 |
Q2 2020 |
$ Change |
% Change |
||||||||||
|
$ |
320.3 |
$ |
283.7 |
$ |
36.6 |
12.9 |
% |
||||||
Adjusted EBITDA |
$ |
109.4 |
$ |
94.5 |
$ |
14.9 |
15.8 |
% |
Lithium net sales of
Current Trends: Full-year 2021 volume growth is expected to be in the mid-teens year-over-year due to North American plant restarts, productivity improvements, and tolling. Average realized pricing is expected to increase sequentially but remain flat compared to 2020. Full-year 2021 adjusted EBITDA is expected to grow between 10% and 15% year over year. Full-year 2021 average margin is expected to remain below 35% due to higher lithium costs related to project start-ups and tolling costs partially offset by efficiency improvements.
Albemarle's Wave 2 growth projects continue to progress. La Negra III/IV is in the commissioning phase and Kemerton I remains on track for construction completion later this year. To mitigate risks related to labor shortages and COVID-19 travel restrictions in
Bromine Specialties
In millions |
Q2 2021 |
Q2 2020 |
$ Change |
% Change |
||||||||||
|
$ |
279.7 |
$ |
232.8 |
$ |
47.0 |
20.2 |
% |
||||||
Adjusted EBITDA |
$ |
92.6 |
$ |
73.0 |
$ |
19.6 |
26.8 |
% |
Bromine net sales of
Current Trends: The company expects full-year 2021 adjusted EBITDA growth in the mid-single digits year-over-year, below previous outlook primarily due to a force majeure declaration by our chlorine supplier in the
Catalysts
In millions |
Q2 2021 |
Q2 2020 |
$ Change |
% Change |
||||||||||
|
$ |
148.3 |
$ |
197.1 |
$ |
(48.7) |
(24.7) |
% |
||||||
Adjusted EBITDA |
$ |
21.2 |
$ |
22.8 |
$ |
(1.6) |
(7.1) |
% |
Catalysts net sales of
Current Trends: The company continues to expect full-year 2021 adjusted EBITDA to decline by between 30% and 40%. Market conditions are improving, but results are expected to be down from prior year primarily due to the impact of the
All Other
In millions |
Q2 2021 |
Q2 2020 |
$ Change |
% Change |
||||||||||
|
$ |
25.5 |
$ |
50.5 |
$ |
(25.0) |
(49.6) |
% |
||||||
Adjusted EBITDA |
$ |
8.4 |
$ |
18.6 |
$ |
(10.2) |
(54.9) |
% |
Other operations represents the company's recently sold
Balance Sheet and Liquidity
As of
Cash Flow and Capital Deployment
Cash from operations for the six months ended
Albemarle's primary capital allocation priorities are to grow profitably, fund its dividend, and maintain its financial flexibility and our Investment Grade credit rating.
In May, the board declared a quarterly dividend of
Earnings Call
Date: |
|
Time: |
|
Dial-in ( |
844-347-1034 |
Dial-in (International): |
209-905-5910 |
Passcode: |
6747789 |
The company's earnings presentation and supporting material are available on Albemarle's website at https://investors.albemarle.com.
About Albemarle
We regularly post information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations,
Forward-Looking Statements
Some of the information presented in this press release, the conference call and discussions that follow, including, without limitation, information related to the timing of active and proposed projects, product development, production capacity, committed volumes, market trends, pricing, financial flexibility, expected growth, anticipated return on opportunities, earnings and demand for our products, input costs, productivity improvements, surcharges, tax rates, stock repurchases, dividends, cash flow generation, costs and cost synergies, capital projects, future acquisition and divestiture transactions, expected benefits from proposed transactions, economic trends, outlook and all other information relating to matters that are not historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the views expressed. Factors that could cause actual results to differ materially from the outlook expressed or implied in any forward-looking statement include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products or the end-user markets in which our products are sold; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; increases in the cost of raw materials and energy, and our ability to pass through such increases to our customers; changes in our markets in general; fluctuations in foreign currencies; changes in laws and government regulation impacting our operations or our products; the occurrence of regulatory actions, proceedings, claims or litigation; the occurrence of cyber-security breaches, terrorist attacks, industrial accidents, natural disasters or climate change; hazards associated with chemicals manufacturing; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest affecting the global economy, including adverse effects from terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings and changes in tax laws and rates; changes in monetary policies, inflation or interest rates that may impact our ability to raise capital or increase our cost of funds, impact the performance of our pension fund investments and increase our pension expense and funding obligations; volatility and uncertainties in the debt and equity markets; technology or intellectual property infringement, including cyber-security breaches, and other innovation risks; decisions we may make in the future; the ability to successfully execute, operate and integrate acquisitions and divestitures; uncertainties as to the duration and impact of the coronavirus (COVID-19) pandemic; and the other factors detailed from time to time in the reports we file with the
Consolidated Statements of Income
(In Thousands Except Per Share Amounts) (Unaudited)
Three Months Ended |
Six Months Ended |
||||||||||||||
|
|
||||||||||||||
2021 |
2020 |
2021 |
2020 |
||||||||||||
Net sales |
$ |
773,896 |
$ |
764,049 |
$ |
1,603,187 |
$ |
1,502,894 |
|||||||
Cost of goods sold |
525,479 |
530,690 |
1,091,083 |
1,027,517 |
|||||||||||
Gross profit |
248,417 |
233,359 |
512,104 |
475,377 |
|||||||||||
Selling, general and administrative expenses |
121,516 |
106,949 |
214,703 |
208,826 |
|||||||||||
Research and development expenses |
13,976 |
14,210 |
28,612 |
30,307 |
|||||||||||
Gain on sale of business |
(429,408) |
— |
(429,408) |
— |
|||||||||||
Operating profit |
542,333 |
112,200 |
698,197 |
236,244 |
|||||||||||
Interest and financing expenses |
(7,152) |
(17,852) |
(51,034) |
(34,737) |
|||||||||||
Other income (expense), net |
14 |
(6,273) |
11,326 |
2,041 |
|||||||||||
Income before income taxes and equity in net income of unconsolidated investments |
535,195 |
88,075 |
658,489 |
203,548 |
|||||||||||
Income tax expense |
106,985 |
15,431 |
129,092 |
33,873 |
|||||||||||
Income before equity in net income of unconsolidated investments |
428,210 |
72,644 |
529,397 |
169,675 |
|||||||||||
Equity in net income of unconsolidated investments (net of tax) |
17,998 |
31,114 |
34,509 |
57,718 |
|||||||||||
Net income |
446,208 |
103,758 |
563,906 |
227,393 |
|||||||||||
Net income attributable to noncontrolling interests |
(21,608) |
(18,134) |
(43,629) |
(34,565) |
|||||||||||
Net income attributable to |
$ |
424,600 |
$ |
85,624 |
$ |
520,277 |
$ |
192,828 |
|||||||
Basic earnings per share |
$ |
3.63 |
$ |
0.81 |
$ |
4.54 |
$ |
1.81 |
|||||||
Diluted earnings per share |
$ |
3.62 |
$ |
0.80 |
$ |
4.51 |
$ |
1.81 |
|||||||
Weighted-average common shares outstanding – basic |
116,809 |
106,329 |
114,700 |
106,278 |
|||||||||||
Weighted-average common shares outstanding – diluted |
117,436 |
106,535 |
115,383 |
106,524 |
Condensed Consolidated Balance Sheets
(In Thousands) (Unaudited)
|
|
||||||
2021 |
2020 |
||||||
ASSETS |
|||||||
Current assets: |
|||||||
Cash and cash equivalents |
$ |
823,572 |
$ |
746,724 |
|||
Trade accounts receivable |
455,222 |
530,838 |
|||||
Other accounts receivable |
58,256 |
61,958 |
|||||
Inventories |
732,563 |
750,237 |
|||||
Other current assets |
81,741 |
116,427 |
|||||
Total current assets |
2,151,354 |
2,206,184 |
|||||
Property, plant and equipment |
7,596,684 |
7,427,641 |
|||||
Less accumulated depreciation and amortization |
2,086,085 |
2,073,016 |
|||||
Net property, plant and equipment |
5,510,599 |
5,354,625 |
|||||
Investments |
907,080 |
656,244 |
|||||
Other assets |
256,081 |
219,268 |
|||||
|
1,640,720 |
1,665,520 |
|||||
Other intangibles, net of amortization |
331,092 |
349,105 |
|||||
Total assets |
$ |
10,796,926 |
$ |
10,450,946 |
|||
LIABILITIES AND EQUITY |
|||||||
Current liabilities: |
|||||||
Accounts payable |
$ |
535,153 |
$ |
483,221 |
|||
Accrued expenses |
317,954 |
440,763 |
|||||
Current portion of long-term debt |
623 |
804,677 |
|||||
Dividends payable |
45,428 |
40,937 |
|||||
Income taxes payable |
85,770 |
32,251 |
|||||
Total current liabilities |
984,928 |
1,801,849 |
|||||
Long-term debt |
2,043,794 |
2,767,381 |
|||||
Postretirement benefits |
47,371 |
48,075 |
|||||
Pension benefits |
309,712 |
340,818 |
|||||
Other noncurrent liabilities |
616,912 |
629,377 |
|||||
Deferred income taxes |
428,438 |
394,852 |
|||||
Commitments and contingencies |
|||||||
Equity: |
|||||||
|
|||||||
Common stock |
1,169 |
1,069 |
|||||
Additional paid-in capital |
2,907,981 |
1,438,038 |
|||||
Accumulated other comprehensive loss |
(328,001) |
(326,132) |
|||||
Retained earnings |
3,584,400 |
3,155,252 |
|||||
|
6,165,549 |
4,268,227 |
|||||
Noncontrolling interests |
200,222 |
200,367 |
|||||
Total equity |
6,365,771 |
4,468,594 |
|||||
Total liabilities and equity |
$ |
10,796,926 |
$ |
10,450,946 |
Selected Consolidated Cash Flow Data
(In Thousands) (Unaudited)
Six Months Ended |
|||||||
2021 |
2020 |
||||||
Cash and cash equivalents at beginning of year |
$ |
746,724 |
$ |
613,110 |
|||
Cash flows from operating activities: |
|||||||
Net income |
563,906 |
227,393 |
|||||
Adjustments to reconcile net income to cash flows from operating activities: |
|||||||
Depreciation and amortization |
123,683 |
111,535 |
|||||
Gain on sale of business |
(429,408) |
— |
|||||
Stock-based compensation and other |
8,425 |
9,765 |
|||||
Equity in net income of unconsolidated investments (net of tax) |
(34,509) |
(57,718) |
|||||
Dividends received from unconsolidated investments and nonmarketable securities |
27,420 |
12,984 |
|||||
Pension and postretirement benefit |
(8,465) |
(3,312) |
|||||
Pension and postretirement contributions |
(20,266) |
(6,692) |
|||||
Unrealized gain on investments in marketable securities |
(2,384) |
(1,278) |
|||||
Loss on early extinguishment of debt |
28,955 |
— |
|||||
Deferred income taxes |
27,708 |
8,990 |
|||||
Working capital changes |
7,942 |
(156,579) |
|||||
Non-cash transfer of 40% value of construction in progress of Kemerton plant to MRL |
96,185 |
87,750 |
|||||
Other, net |
(3,339) |
(24,921) |
|||||
Net cash provided by operating activities |
385,853 |
207,917 |
|||||
Cash flows from investing activities: |
|||||||
Acquisitions, net of cash acquired |
— |
(22,572) |
|||||
Capital expenditures |
(396,915) |
(418,991) |
|||||
Cash proceeds from divestitures, net |
290,467 |
— |
|||||
Sales of marketable securities, net |
4,553 |
1,496 |
|||||
Investments in equity and other corporate investments |
(286) |
(486) |
|||||
Net cash used in investing activities |
(102,181) |
(440,553) |
|||||
Cash flows from financing activities: |
|||||||
Proceeds from issuance of common stock |
1,453,888 |
— |
|||||
Repayments of long-term debt and credit agreements |
(1,173,823) |
— |
|||||
Proceeds from borrowings of credit agreements |
— |
452,163 |
|||||
Other debt repayments, net |
(325,316) |
12,956 |
|||||
Fees related to early extinguishment of debt |
(24,877) |
— |
|||||
Dividends paid to shareholders |
(86,637) |
(79,909) |
|||||
Dividends paid to noncontrolling interests |
(43,698) |
(14,286) |
|||||
Proceeds from exercise of stock options |
14,335 |
10,809 |
|||||
Withholding taxes paid on stock-based compensation award distributions |
(7,047) |
(4,019) |
|||||
Other |
(1,359) |
(2,669) |
|||||
Net cash (used in) provided by financing activities |
(194,534) |
375,045 |
|||||
Net effect of foreign exchange on cash and cash equivalents |
(12,290) |
(18,823) |
|||||
Increase in cash and cash equivalents |
76,848 |
123,586 |
|||||
Cash and cash equivalents at end of period |
$ |
823,572 |
$ |
736,696 |
Consolidated Summary of Segment Results
(In Thousands) (Unaudited)
Three Months Ended |
Six Months Ended |
||||||||||||||
|
|
||||||||||||||
2021 |
2020 |
2021 |
2020 |
||||||||||||
Net sales: |
|||||||||||||||
Lithium |
$ |
320,334 |
$ |
283,722 |
$ |
599,310 |
$ |
520,540 |
|||||||
Bromine Specialties |
279,748 |
232,779 |
560,195 |
464,371 |
|||||||||||
Catalysts |
148,344 |
197,053 |
368,587 |
404,260 |
|||||||||||
All Other |
25,470 |
50,495 |
75,095 |
113,723 |
|||||||||||
Total net sales |
$ |
773,896 |
$ |
764,049 |
$ |
1,603,187 |
$ |
1,502,894 |
|||||||
Adjusted EBITDA: |
|||||||||||||||
Lithium |
$ |
109,441 |
$ |
94,536 |
$ |
215,877 |
$ |
173,173 |
|||||||
Bromine Specialties |
92,646 |
73,041 |
187,286 |
156,303 |
|||||||||||
Catalysts |
21,164 |
22,777 |
46,591 |
70,247 |
|||||||||||
All Other |
8,379 |
18,598 |
29,858 |
41,422 |
|||||||||||
Corporate |
(37,002) |
(23,759) |
(54,930) |
(59,587) |
|||||||||||
Total adjusted EBITDA |
$ |
194,628 |
$ |
185,193 |
$ |
424,682 |
$ |
381,558 |
See accompanying non-GAAP reconciliations below.
Additional Information
It should be noted that adjusted net income attributable to
A description of other non-GAAP financial measures that Albemarle uses to evaluate its operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP can be found on the following pages of this press release, which is also is available on Albemarle's website at https://investors.albemarle.com. The company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the company is unable to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the company's results calculated in accordance with GAAP.
ALBEMARLE CORPORATION AND SUBSIDIARIES
Non-GAAP Reconciliations
(Unaudited)
See below for a reconciliation of adjusted net income attributable to
Three Months Ended |
Six Months Ended |
||||||||||||||
|
|
||||||||||||||
In thousands, except percentages and per share amounts |
2021 |
2020 |
2021 |
2020 |
|||||||||||
Net income attributable to |
$ |
424,600 |
$ |
85,624 |
$ |
520,277 |
$ |
192,828 |
|||||||
Add back: |
|||||||||||||||
Non-operating pension and OPEB items (net of tax) |
(4,273) |
(2,299) |
(8,540) |
(4,610) |
|||||||||||
Non-recurring and other unusual items (net of tax) |
(315,996) |
7,907 |
(283,235) |
9,400 |
|||||||||||
Adjusted net income attributable to |
$ |
104,331 |
$ |
91,232 |
$ |
228,502 |
$ |
197,618 |
|||||||
Adjusted diluted earnings per share |
$ |
0.89 |
$ |
0.86 |
$ |
1.98 |
$ |
1.86 |
|||||||
Weighted-average common shares outstanding – diluted |
117,436 |
106,535 |
115,383 |
106,524 |
|||||||||||
Net income attributable to |
$ |
424,600 |
$ |
85,624 |
$ |
520,277 |
$ |
192,828 |
|||||||
Add back: |
|||||||||||||||
Interest and financing expenses |
7,152 |
17,852 |
51,034 |
34,737 |
|||||||||||
Income tax expense |
106,985 |
15,431 |
129,092 |
33,873 |
|||||||||||
Depreciation and amortization |
61,423 |
57,841 |
123,683 |
111,535 |
|||||||||||
EBITDA |
600,160 |
176,748 |
824,086 |
372,973 |
|||||||||||
Non-operating pension and OPEB items |
(5,471) |
(2,895) |
(10,936) |
(5,803) |
|||||||||||
Non-recurring and other unusual items |
(400,061) |
11,340 |
(388,468) |
14,388 |
|||||||||||
Adjusted EBITDA |
$ |
194,628 |
$ |
185,193 |
$ |
424,682 |
$ |
381,558 |
|||||||
Net sales |
$ |
773,896 |
$ |
764,049 |
$ |
1,603,187 |
$ |
1,502,894 |
|||||||
EBITDA margin |
77.6 |
% |
23.1 |
% |
51.4 |
% |
24.8 |
% |
|||||||
Adjusted EBITDA margin |
25.1 |
% |
24.2 |
% |
26.5 |
% |
25.4 |
% |
See below for a reconciliation of adjusted EBITDA on a segment basis, the non-GAAP financial measure, to Net income attributable to
Lithium |
Bromine |
Catalysts |
Reportable |
All |
Corporate |
Consolidated |
% of |
|||||||||||||||||||||||
Three months ended |
||||||||||||||||||||||||||||||
Net income (loss) attributable to |
$ |
74,593 |
$ |
80,148 |
$ |
8,446 |
$ |
163,187 |
$ |
7,972 |
$ |
253,441 |
$ |
424,600 |
54.9 |
% |
||||||||||||||
Depreciation and amortization |
33,497 |
12,498 |
12,718 |
58,713 |
407 |
2,303 |
61,423 |
7.9 |
% |
|||||||||||||||||||||
Non-recurring and other unusual items |
1,351 |
— |
— |
1,351 |
— |
(401,412) |
(400,061) |
(51.7) |
% |
|||||||||||||||||||||
Interest and financing expenses |
— |
— |
— |
— |
— |
7,152 |
7,152 |
0.9 |
% |
|||||||||||||||||||||
Income tax expense |
— |
— |
— |
— |
— |
106,985 |
106,985 |
13.8 |
% |
|||||||||||||||||||||
Non-operating pension and OPEB items |
— |
— |
— |
— |
— |
(5,471) |
(5,471) |
(0.7) |
% |
|||||||||||||||||||||
Adjusted EBITDA |
$ |
109,441 |
$ |
92,646 |
$ |
21,164 |
$ |
223,251 |
$ |
8,379 |
$ |
(37,002) |
$ |
194,628 |
25.1 |
% |
||||||||||||||
Three months ended |
||||||||||||||||||||||||||||||
Net income (loss) attributable to |
$ |
66,038 |
$ |
60,692 |
$ |
10,702 |
$ |
137,432 |
$ |
16,425 |
$ |
(68,233) |
$ |
85,624 |
11.2 |
% |
||||||||||||||
Depreciation and amortization |
28,498 |
12,349 |
12,075 |
52,922 |
2,173 |
2,746 |
57,841 |
7.6 |
% |
|||||||||||||||||||||
Non-recurring and other unusual items |
— |
— |
— |
— |
— |
11,340 |
11,340 |
1.5 |
% |
|||||||||||||||||||||
Interest and financing expenses |
— |
— |
— |
— |
— |
17,852 |
17,852 |
2.3 |
% |
|||||||||||||||||||||
Income tax expense |
— |
— |
— |
— |
— |
15,431 |
15,431 |
2.1 |
% |
|||||||||||||||||||||
Non-operating pension and OPEB items |
— |
— |
— |
— |
— |
(2,895) |
(2,895) |
(0.4) |
% |
|||||||||||||||||||||
Adjusted EBITDA |
$ |
94,536 |
$ |
73,041 |
$ |
22,777 |
$ |
190,354 |
$ |
18,598 |
$ |
(23,759) |
$ |
185,193 |
24.2 |
% |
||||||||||||||
Six months ended |
||||||||||||||||||||||||||||||
Net income (loss) attributable to |
$ |
144,965 |
$ |
162,261 |
$ |
21,362 |
$ |
328,588 |
$ |
27,988 |
$ |
163,701 |
$ |
520,277 |
32.5 |
% |
||||||||||||||
Depreciation and amortization |
65,303 |
25,025 |
25,229 |
115,557 |
1,870 |
6,256 |
123,683 |
7.7 |
% |
|||||||||||||||||||||
Non-recurring and other unusual items |
5,609 |
— |
— |
5,609 |
— |
(394,077) |
(388,468) |
(24.2) |
% |
|||||||||||||||||||||
Interest and financing expenses |
— |
— |
— |
— |
— |
51,034 |
51,034 |
3.2 |
% |
|||||||||||||||||||||
Income tax expense |
— |
— |
— |
— |
— |
129,092 |
129,092 |
8.1 |
% |
|||||||||||||||||||||
Non-operating pension and OPEB items |
— |
— |
— |
— |
— |
(10,936) |
(10,936) |
(0.7) |
% |
|||||||||||||||||||||
Adjusted EBITDA |
$ |
215,877 |
$ |
187,286 |
$ |
46,591 |
$ |
449,754 |
$ |
29,858 |
$ |
(54,930) |
$ |
424,682 |
26.5 |
% |
||||||||||||||
Six months ended |
||||||||||||||||||||||||||||||
Net income (loss) attributable to |
$ |
119,278 |
$ |
132,357 |
$ |
45,594 |
$ |
297,229 |
$ |
37,271 |
$ |
(141,672) |
$ |
192,828 |
12.8 |
% |
||||||||||||||
Depreciation and amortization |
53,895 |
23,946 |
24,653 |
102,494 |
4,151 |
4,890 |
111,535 |
7.4 |
% |
|||||||||||||||||||||
Non-recurring and other unusual items |
— |
— |
— |
— |
— |
14,388 |
14,388 |
1.0 |
% |
|||||||||||||||||||||
Interest and financing expenses |
— |
— |
— |
— |
— |
34,737 |
34,737 |
2.3 |
% |
|||||||||||||||||||||
Income tax expense |
— |
— |
— |
— |
— |
33,873 |
33,873 |
2.3 |
% |
|||||||||||||||||||||
Non-operating pension and OPEB items |
— |
— |
— |
— |
— |
(5,803) |
(5,803) |
(0.4) |
% |
|||||||||||||||||||||
Adjusted EBITDA |
$ |
173,173 |
$ |
156,303 |
$ |
70,247 |
$ |
399,723 |
$ |
41,422 |
$ |
(59,587) |
$ |
381,558 |
25.4 |
% |
Non-operating pension and OPEB items, consisting of mark-to-market actuarial gains/losses, settlements/curtailments, interest cost and expected return on assets, are not allocated to Albemarle's operating segments and are included in the Corporate category. In addition, the company believes that these components of pension cost are mainly driven by market performance, and the company manages these separately from the operational performance of the company's businesses. In accordance with GAAP, these non-operating pension and OPEB items are included in Other income (expenses), net. Non-operating pension and OPEB items were as follows (in thousands):
Three Months Ended |
Six Months Ended |
||||||||||||||
|
|
||||||||||||||
2021 |
2020 |
2021 |
2020 |
||||||||||||
Interest cost |
$ |
5,430 |
$ |
7,133 |
$ |
10,858 |
$ |
14,288 |
|||||||
Expected return on assets |
(10,901) |
(10,028) |
(21,794) |
(20,091) |
|||||||||||
Total |
$ |
(5,471) |
$ |
(2,895) |
$ |
(10,936) |
$ |
(5,803) |
In addition to the non-operating pension and OPEB items disclosed above, the company has identified certain other items and excluded them from Albemarle's adjusted net income calculation for the periods presented. A listing of these items, as well as a detailed description of each follows below (per diluted share):
Three Months Ended |
Six Months Ended |
||||||||||||||
|
|
||||||||||||||
2021 |
2020 |
2021 |
2020 |
||||||||||||
Restructuring and other(1) |
$ |
— |
$ |
0.04 |
$ |
0.01 |
$ |
0.06 |
|||||||
Acquisition and integration related costs(2) |
0.01 |
0.04 |
0.03 |
0.06 |
|||||||||||
|
0.13 |
— |
0.13 |
— |
|||||||||||
Gain on sale of business(4) |
(2.82) |
— |
(2.87) |
— |
|||||||||||
Loss on early extinguishment of debt(5) |
0.01 |
— |
0.21 |
— |
|||||||||||
Other(6) |
0.04 |
(0.01) |
0.10 |
(0.02) |
|||||||||||
Discrete tax items(7) |
(0.06) |
— |
(0.06) |
(0.01) |
|||||||||||
Total non-recurring and other unusual items |
$ |
(2.69) |
$ |
0.07 |
$ |
(2.45) |
$ |
0.09 |
(1) |
During the three and six months ended |
|
(2) |
Costs related to the acquisition, integration and potential divestitures of various significant projects, recorded in Selling, general and administrative expenses for the three and six months ended |
|
(3) |
Included in Selling, general and administrative expenses for the three and six months ended |
|
(4) |
Included in Gain on sale of business, for the three and six months ended |
|
(5) |
Included in Interest and financing expenses for the three and six months ended |
|
(6) |
Other adjustments for the three months ended |
|
• |
Selling, general and administrative expenses - |
|
• |
Other income, net - |
|
After income taxes, these charges totaled |
||
Other adjustments for the six months ended |
||
• |
Selling, general and administrative expenses - |
|
• |
Other income, net - |
|
After income taxes, these charges totaled |
||
Other adjustments for the three months ended |
||
• |
Other expenses, net - |
|
Other adjustments for the six months ended |
||
• |
Other expenses, net - |
|
After income taxes, these net gains totaled |
||
(7) |
Included in Income tax expense for the three and six months ended |
|
Included in Income tax expense for the three and six months ended |
See below for a reconciliation of the adjusted effective income tax rate, the non-GAAP financial measure, to the effective income tax rate, the most directly comparable financial measure calculated and reported in accordance with GAAP (in thousands, except percentages).
Income before |
Income tax |
Effective income |
||||||||
Three months ended |
||||||||||
As reported |
$ |
535,195 |
$ |
106,985 |
20.0 |
% |
||||
Non-recurring, other unusual and non-operating pension and OPEB items |
(404,383) |
(84,114) |
||||||||
As adjusted |
$ |
130,812 |
$ |
22,871 |
17.5 |
% |
||||
Three months ended |
||||||||||
As reported |
$ |
88,075 |
$ |
15,431 |
17.5 |
% |
||||
Non-recurring, other unusual and non-operating pension and OPEB items |
8,445 |
2,837 |
||||||||
As adjusted |
$ |
96,520 |
$ |
18,268 |
18.9 |
% |
||||
Six months ended |
||||||||||
As reported |
$ |
658,489 |
$ |
129,092 |
19.6 |
% |
||||
Non-recurring, other unusual and non-operating pension and OPEB items |
(370,457) |
(78,682) |
||||||||
As adjusted |
$ |
288,032 |
$ |
50,410 |
17.5 |
% |
||||
Six months ended |
||||||||||
As reported |
$ |
203,548 |
$ |
33,873 |
16.6 |
% |
||||
Non-recurring, other unusual and non-operating pension and OPEB items |
8,906 |
3,795 |
||||||||
As adjusted |
$ |
212,454 |
$ |
37,668 |
17.7 |
% |
View original content to download multimedia:https://www.prnewswire.com/news-releases/albemarle-reports-second-quarter-results-301348671.html
SOURCE
David Burke, 980.299.5533